Thats where BPC-157 sprays come in
En humanos, los ensayos clnicos de fase II en obesidad evaluaron distintas dosis: si bien se observaron seales de reduccin de peso y un buen perfil de tolerancia, los estudios no alcanzaron de forma robusta los criterios de valoracin primarios de eficacia, lo que detuvo su desarrollo como frmaco anti-obesidad
Dual GIP/GLP-1 Receptor Agonists The first GIP/GLP-1 receptor co-agonist was discovered in 2013, exhibiting significantly more pronounced glucose-lowering and insulin-releasing efficacy than selective GLP-1 receptor agonists in obese and leptin receptor-deficient mouse models, as well as in humans [91]
Lab Tested to the Max for Safety and Quality To keep the peptide safe, each batch has to pass tough lab tests
20 mg vial Concentration: 20 mg 3 mL = 6.667 mg/mL (equivalently 6,667 mcg/mL) Dose in mg: 250 mcg = 0.25 mg Draw volume: 0.25 mg 6.667 mg/mL = 0.0375 mL Syringe units: 0.0375 mL 100 = 3.75 units 4 units on a U-100 syringe On the 20 mg vial, one documented dose is a very small draw about the 4-unit mark
Here are the primary ways therapy can enhance your daily life
